Home
Clinical Trials
Randomized Therapy In Status ...

Randomized Therapy In Status Epilepticus

Last Updated: 2025-05-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-09

Study Completion Date

2024-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

NCT03350035

Status Epilepticus Convulsive Status EPILEPTICUS Non Convulsive Status Epilepticus +1 more

COMPLETED PHASE2

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

NCT05814523

Refractory Status Epilepticus

WITHDRAWN PHASE3

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

NCT00465517

Partial Epilepsy Catamenial Epilepsy

COMPLETED PHASE2

Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)

NCT05757544

Status Epilepticus

WITHDRAWN PHASE2

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208

Drug Resistant Partial Onset Seizure

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of IV ganaxolone in status epilepticus. Investigational product was added to standard of care following failure of any two or more antiseizure medications (benzodiazepine and one IV antiepileptic drug (AED) or two IV AEDs. Participants were screened for inclusion/exclusion criteria prior to receiving investigational product by continuous IV infusion. Participants were followed for approximately 4 weeks. Participants who are known to be at risk for SE were consented or assented prior to an SE event.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Status Epilepticus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IV Placebo

Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

IV ganaxolone active

Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper

Group Type EXPERIMENTAL

Ganaxolone

Intervention Type DRUG

Ganaxolone will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ganaxolone

Ganaxolone will be administered.

Intervention Type DRUG

Placebo

Placebo will be administered.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant, participant's parent, guardian, or legal authorized representative (LAR) must provide signed of informed consent/assent, and once capable (per institution guidelines), there must be documentation of consent/assent by the participant demonstrating they are willing and aware of the investigational nature of the study and related procedures. Where allowed by law, where the participant lacks the capacity to make informed decisions regarding his/her medical treatment options, the treating clinician may follow their deferred consenting practices. The clinician will make the final decision based on the best interests of the particiapant.
2. Male or females 12 years of age and older at the time of the first dose of IP
3. SE meeting the following criteria:

a. A diagnosis of SE with or without prominent motor features based on clinical and EEG findings:

i. Diagnosis is established by:
* For SE with prominent motor features: Clinical and EEG seizure activity indicative of convulsive, myoclonic or focal motor SE.
* For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of non-convulsive status epilepticus (NCSE)

ii. For any type of SE:
* At least 6 minutes of cumulative seizure activity over a 30-minute period within the hour before IP initiation, AND
* Seizure activity during the 30 minutes immediately prior to IP initiation

b. The treating clinician(s) anticipate that IV anesthesia is likely to be the next treatment for SE that persists following initiation of IP
4. Participants must have received any two or more of the following agents for treatment of the current episode of SE administered at an adequate dose and for a sufficient duration, in the judgment of the investigator, to demonstrate efficacy

* Benzodiazepines,
* IV Fosphenytoin/phenytoin,
* IV Valproic acid,
* IV Levetiracetam,
* IV Lacosamide,
* IV Brivaracetam, or
* IV Phenobarbital
5. Body mass index (BMI) \< 40 or, if BMI is not able to be calculated at screening, participant is assessed by investigator as not morbidly obese

Exclusion Criteria

1. Life expectancy of less than 24 hours
2. Anoxic brain injury or an uncorrected rapidly reversable metabolic condition as the primary cause of SE (e.g., hypoglycemia \< 50 milligram per deciliter \[mg/dL\] or hyperglycemia \> 400 mg/dL)
3. Participants who have received high-dose IV anesthetics (e.g., midazolam, propofol, thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high-dose IV anesthetics.
4. Clinical condition or advance directive that would NOT permit use of IV anesthesia
5. Participants known or suspected to be pregnant
6. Participants with known allergy or sensitivity to progesterone or allopregnanolone medications/supplements
7. Receiving a concomitant IV product containing Captisol®
8. Known or suspected hepatic insufficiency or hepatic failure leading to impaired synthetic liver function.
9. Known or suspected stage 3B (moderate to severe; estimated glomerular filtration rate \[eGFR\] 44-30 milliliter/minutes/1.73-meter square \[mL/min/1.73m\^2\]), stage 4 (severe; eGFR 29-15 mL/min/1.73m\^2), or stage 5 (kidney failure; eGFR \< 15 mL/min/1.73m\^2 or dialysis) kidney disease
10. Use of an investigational product for which less than 30 days or 5 half-lives have elapsed from the final product administration. Participation in a non-interventional clinical study does not exclude eligibility.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marinus Research Site

Birmingham, Alabama, United States

Site Status

Marinus Research Site

Phoenix, Arizona, United States

Site Status

Marinus Research Site

Little Rock, Arkansas, United States

Site Status

Marinus Research Site

Downey, California, United States

Site Status

Marinus Research Site

La Jolla, California, United States

Site Status

Marinus Research Site

Orange, California, United States

Site Status

Marinus Research Site

Sacramento, California, United States

Site Status

Marinus Research Site

Aurora, Colorado, United States

Site Status

Marinus Research Site

Denver, Colorado, United States

Site Status

Marinus Research Site

New Haven, Connecticut, United States

Site Status

Marinus Research Site

Gainesville, Florida, United States

Site Status

Marinus Research Site #1

Miami, Florida, United States

Site Status

Marinus Research Site

Miami, Florida, United States

Site Status

Marinus Research Site

Miami, Florida, United States

Site Status

Marinus Research Site

Port Saint Lucie, Florida, United States

Site Status

Marinus Research Site

Tampa, Florida, United States

Site Status

Marinus Research Site

Chicago, Illinois, United States

Site Status

Marinus Research Site

Chicago, Illinois, United States

Site Status

Marinus Research Site

Urbana, Illinois, United States

Site Status

Marinus Research Site

Louisville, Kentucky, United States

Site Status

Marinus Research Site

New Orleans, Louisiana, United States

Site Status

Marinus Research Site

Shreveport, Louisiana, United States

Site Status

Marinus Research Site #1

Baltimore, Maryland, United States

Site Status

Marinus Research Site

Baltimore, Maryland, United States

Site Status